|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 651.75 GBX | +0.35% |
|
+6.58% | +40.46% |
| 05-05 | FTSE 100 pulled down by banks amid Iran war worry | AN |
| 04-29 | WINNERS & LOSERS: Pharma in the red; DCC jumps after takeover approach | AN |
| Fiscal Period: April | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Gain (Loss) on Sale of Investment, Total (Rev) | 1.13B | -254M | -107M | 1.15B | 129M | |||||
Interest And Invest. Income (Rev) | 18.16M | 15.9M | 20.02M | 21.91M | 25.36M | |||||
Other Revenues, Total | -49.11M | -5.8M | 34K | -22.03M | 2.77M | |||||
Total Revenues | 1.1B | -244M | -86.75M | 1.15B | 157M | |||||
Gross Profit | 1.1B | -244M | -86.75M | 1.15B | 157M | |||||
Selling General & Admin Expenses, Total | 25.2M | 29.62M | 23.09M | 27.31M | 32.5M | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Other Operating Expenses, Total | 25.2M | 29.62M | 23.09M | 27.31M | 32.5M | |||||
Operating Income | 1.07B | -273M | -110M | 1.12B | 124M | |||||
Interest Expense, Total | -996K | -973K | -1.6M | -1.87M | -1.79M | |||||
Net Interest Expenses | -996K | -973K | -1.6M | -1.87M | -1.79M | |||||
Currency Exchange Gains (Loss) | -4.38M | 17.54M | 8.41M | -1.29M | -1.65M | |||||
EBT, Excl. Unusual Items | 1.07B | -257M | -103M | 1.12B | 121M | |||||
EBT, Incl. Unusual Items | 1.07B | -257M | -103M | 1.12B | 121M | |||||
Income Tax Expense | 2.43M | 2M | 2.15M | 1.94M | 2.37M | |||||
Earnings From Continuing Operations | 1.06B | -259M | -105M | 1.12B | 118M | |||||
Net Income to Company | 1.06B | -259M | -105M | 1.12B | 118M | |||||
Net Income - (IS) | 1.06B | -259M | -105M | 1.12B | 118M | |||||
Net Income to Common Incl Extra Items | 1.06B | -259M | -105M | 1.12B | 118M | |||||
Net Income to Common Excl. Extra Items | 1.06B | -259M | -105M | 1.12B | 118M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.78 | -0.19 | -0.08 | 0.9 | 0.1 | |||||
Basic EPS - Continuing Operations | 0.78 | -0.19 | -0.08 | 0.9 | 0.1 | |||||
Basic Weighted Average Shares Outstanding | 1.37B | 1.35B | 1.29B | 1.23B | 1.19B | |||||
Net EPS - Diluted | 0.78 | -0.19 | -0.08 | 0.9 | 0.1 | |||||
Diluted EPS - Continuing Operations | 0.78 | -0.19 | -0.08 | 0.9 | 0.1 | |||||
Diluted Weighted Average Shares Outstanding | 1.37B | 1.35B | 1.29B | 1.23B | 1.19B | |||||
Normalized Basic EPS | 0.49 | -0.12 | -0.05 | 0.57 | 0.06 | |||||
Normalized Diluted EPS | 0.49 | -0.12 | -0.05 | 0.57 | 0.06 | |||||
Supplemental Items | ||||||||||
EBITA | 1.07B | -273M | -110M | 1.12B | 124M | |||||
EBIT | 1.07B | -273M | -110M | 1.12B | 124M | |||||
Total Revenues (As Reported) | 1.09B | -226M | -78.34M | 1.15B | 155M | |||||
Effective Tax Rate - (Ratio) | 0.23 | -0.78 | -2.08 | 0.17 | 1.96 | |||||
Normalized Net Income | 666M | -160M | -64.4M | 698M | 75.45M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | - | 25K | - | - | - | |||||
Selling and Marketing Expenses | - | 25K | - | - | - | |||||
General and Administrative Expenses | 25.2M | 29.59M | 23.09M | 27.31M | 32.5M | |||||
Research And Development Expense From Footnotes | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















